Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation

Liver Transplantation

Volumn 11, Issue 11, 2005, Pages 1395-1402

  Tanaka, Koichi ^a   Lake, John ^b   Villamil, Federico ^c   Levy, Gary ^d   Marotta, Paul ^e   Mies, Sergio ^f   de Hemptinne, Bernard ^g   Moench, Christian ^h  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; RAPAMYCIN; TACROLIMUS;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MENTAL DISEASE; MICROEMULSION; MULTICENTER STUDY; MYCOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS INFECTION;

ADULT; CROSS-OVER STUDIES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SINGLE-BLIND METHOD; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 30444451903     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20508     Document Type: Article

References (16)

1. Bak T, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, et al. Adult-to-adult living donor liver transplant using right-lobe grafts: Results and lessons learned from a single-center experience. Liver Transpl 2001;7:680-686.
2. Takatsuki M, Chen CL, de Villa VH, Chen YS, Wang CC, Wang H, et al. Neoral-based immunosuppression in living donor liver transplantation. Transplant Proc 2001;33:3450.
3. Broelsch CE, Malago M, Testa G, Gamazo CV. Living donor liver transplantation in adults: Outcome in Europe. Liver Transplant 2000;6(Suppl):S64-S65.
4. Todo S, Furukawa H, Jin MB, Shimamura T. Living donor liver transplantation in adults: Outcome in Japan. Liver Transpl 2000;6(Suppl):S66-S72.
5. Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, et al. Living donor liver transplant recipients achieve relatively high immunosuppressant blood levels than cadaveric recipients. Liver Transplant 2002;8:212-218.
6. Taber DJ, Dupuis RE, Fann AL, Andreoni KA, Gerber DA, Fair JH, et al. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transplant 2002;8:219-223.
7. Marcos A, Ham JM, Fisher RA, Olzinski AT, Posner MP. Single-center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe. Liver Transplant 2000;6:296-301.
8. Hashikura Y, Ogino S, Ikegami T, Nakazawa Y, Urata K, Terada M. Conversion to Neoral from Tacrolimus in patients undergoing living-donor liver transplantation [abstract]. Liver Transpl 2003;9:263.
9. Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, et al. on behalf of the LIS2T Study Group. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004;77:1632-1638.
10. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997;25:658-663.
11. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-1288.
12. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313:42-47.
13. Maniere T, Éthier C, André A, Bilodeau M. Evaluation of the effect of immunosuppressive agents on hepatitis C: Cyclosporin reduces viral replication in the replicon model [abstract]. J Hepatol 2004;40:120.
14. Levy G, Lilly LB, Graft DR, Girgrah NT, Humar A, Greig PD, Cattral MS. The impact of calcineurin inhibitors (CNIs) on recurrent hepatitis C infection. Am J Transplant 2004;4(Suppl 8):410.
15. Taber DJ, Dupuis RE, Fann AL, Andreoni K, Shrestha R, Gerber D, et al. A critical analysis of tacrolimus dosing requirements and concentrations in living donor liver transplant recipients [abstract]. Am J Transplant 2001;1:369A.
16. Morgan GR, John D, Diflo T, Teperman L. Tacrolimus dosage adjustment in adult right lobe liver transplant recipients [abstract]. Am J Transplant 2001;1:369A.